The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
HOME > BUSINESS
BUSINESS
- Chiome to Launch First-in-Human Trial for Anti-DLK-1 Antibody
July 22, 2020
- Shonan iPark’s VC Consortium Now Up and Running
July 22, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Mochida, Shimane Univ. Start Collaborative Research on New Treatment for Joint Disease
July 22, 2020
- Daiichi Sankyo’s Prasugrel Hits Primary Goal in Japan PIII for Thrombotic Stroke, Filing for Label Expansion Planned in 2021
July 22, 2020
- MSD Launches Injectable Version of Deep Mycosis Drug Noxafil
July 22, 2020
- Japan Approves MSD’s 9-Valent HPV Vaccine 5 Years after Filing
July 21, 2020
- Shionogi Triples Coronavirus Vaccine Manufacturing Target, Eyes Doses for 30 Million People Annually
July 21, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- National CV Center Spin-Off Developing Oligonucleotide Therapy for Dyslipidemia, Eyes 1st Trial in FY2022
July 20, 2020
- Mitsubishi Tanabe Earns Indonesian OK for ALS Med
July 17, 2020
- Kyowa Pharma Expanding Focus Beyond Drugs, Eyes New Diagnostic/Treatment Options in CNS
July 17, 2020
- With New Chief at Helm, Mitsubishi Tanabe Looks to Boost Presence in Overseas Markets
July 16, 2020
- Medicago Begins PI Trial of COVID-19 Vaccine in Canada
July 16, 2020
- SanBio to Focus on Cell Therapy SB623 for Brain Injury, Stroke, Seeking Licensees for Other Indications
July 16, 2020
- Astellas to Transfer Antipsychotic Dogmatyl to Nichi-Iko
July 15, 2020
- Eisai Starts PIII Preclinical Alzheimer’s Study for BAN2401
July 15, 2020
- Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
July 14, 2020
- Nichi-Iko Execs Face Pay Cuts over Massive Recalls
July 14, 2020
- Keio Prof. Kenya Honda Becomes Scientific Advisor for 4BIO
July 14, 2020
ページ
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Japan’s pharmaceutical industry has been in dire need of a shake-up, and as we continue to grapple with the COVID-19 pandemic, one thing is remarkably clear. It’s no longer business as usual, and we’re enjoying a front-row seat to some…